Single IV Ketamine for Bipolar Depression: Open Neurocognitive Pilot Study (Permoda-Osip / Rybakowski, Poznan Poland)

This synthetic trial has been added to our database because a psychedelic paper (about a clinical trial) references this trial, but no (live) registration can be found.

The study evaluated the effects of a single 0.5 mg/kg intravenous ketamine infusion on neurocognitive function and depressive symptoms in 18 patients with bipolar I or II disorder experiencing a depressive episode. Participants were receiving mood-stabilising medication at the time of the intervention.

Neurocognitive assessments, including the Stroop colour–word test and Trail Making Test, were conducted at baseline and following the infusion. Results indicated significant improvements in neuropsychological performance by the third day post-infusion, a change that correlated with baseline impairment but was not associated with the reduction of depressive symptoms.